Disease details

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01337986 (ClinicalTrials.gov)	May 2011	13/4/2011	Ampyra for Optic Neuritis in Multiple Sclerosis	Dalfampridine After Optic Neuritis to Improve Visual Function in Multiple Sclerosis	Multiple Sclerosis;Optic Neuritis	Drug: Dalfampridine/Placebo;Drug: Placebo/Dalfampridine	Washington University School of Medicine	Acorda Therapeutics	Completed	18 Years	55 Years	All	53	Phase 2/Phase 3	United States
2	EUCTR2010-023678-38-IT (EUCTR)	20/04/2011	02/02/2011	High-field structural and functional MRI to investigate the substrates of fatigue in multiple sclerosis and to monitor the effect of tailored treatments.Pharmacological substudy. - ND	High-field structural and functional MRI to investigate the substrates of fatigue in multiple sclerosis and to monitor the effect of tailored treatments.Pharmacological substudy. - ND	patients with multiple sclerosis MedDRA version: 9.1;Level: PT;Classification code 10028245	Trade Name: MANTADAN*20CPR 100MG INN or Proposed INN: Amantadine Trade Name: AMPYRA INN or Proposed INN: Ampyra	FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR	NULL	Not Recruiting			Female: yes Male: yes			Italy